{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:16:02Z","timestamp":1792440962146,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s10194-016-0591-3","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T20:06:41Z","timestamp":1453320401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience"],"prefix":"10.1186","volume":"17","author":[{"given":"Andrea","family":"Negro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Curto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Lionetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,21]]},"reference":[{"key":"591_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","unstructured":"Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743\u2013800","journal-title":"Lancet"},{"key":"591_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-015-0544-2","volume":"16","author":"TJ Steiner","year":"2015","unstructured":"Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P (2015) Headache disorders are third cause of disability worldwide. J Headache Pain 16:58","journal-title":"J Headache Pain"},{"key":"591_CR3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"JL Natoli","year":"2010","unstructured":"Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599\u2013609","journal-title":"Cephalalgia"},{"key":"591_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428\u2013432","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"591_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia 31:301\u2013315","journal-title":"Cephalalgia"},{"key":"591_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/JOM.0b013e3181c1dc56","volume":"52","author":"WF Stewart","year":"2010","unstructured":"Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB (2010) Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 52:8\u201314","journal-title":"J Occup Environ Med"},{"key":"591_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(04)00824-5","volume":"3","author":"HC Deiner","year":"2004","unstructured":"Deiner HC, Limmroth V (2004) Medication overuse headache: a worldwide problem. Lancet Neurol 3:475\u2013483","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"591_CR8","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1007\/s11739-010-0457-7","volume":"5","author":"A Negro","year":"2010","unstructured":"Negro A, D\u2019Alonzo L, Martelletti P (2010) Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med 5(Suppl 1):S13\u2013S19","journal-title":"Intern Emerg Med"},{"key":"591_CR9","first-page":"1401","volume":"15","author":"A Negro","year":"2011","unstructured":"Negro A, Rocchietti-March M, Fiorillo M, Martelletti P (2011) Chronic migraine: current concepts and ongoing treatments. Eur Rev Med Pharmacol Sci 15:1401\u20131420","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"591_CR10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1468-2982.2006.01190.x","volume":"26","author":"P Zeeberg","year":"2006","unstructured":"Zeeberg P, Olesen J, Jensen R (2006) Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 26:1192\u20131198","journal-title":"Cephalalgia"},{"key":"591_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71:559\u2013566","journal-title":"Neurology"},{"key":"591_CR12","volume-title":"BOTOX (onabotulinumtoxinA) full prescribing information","author":"Allergan Inc","year":"2013","unstructured":"Allergan Inc (2013) BOTOX (onabotulinumtoxinA) full prescribing information. Allergan Inc, Irvine"},{"key":"591_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793\u2013803","journal-title":"Cephalalgia"},{"key":"591_CR14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for threat- ment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804\u2013814","journal-title":"Cephalalgia"},{"key":"591_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, ran- domized placebo-controlled phases of the PREEMPT clinical program. Headache 50:921\u2013936","journal-title":"Headache"},{"key":"591_CR16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ (2010) Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406\u20131418","journal-title":"Headache"},{"key":"591_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.brainresrev.2004.09.007","volume":"48","author":"L Edvinsson","year":"2005","unstructured":"Edvinsson L, Uddman R (2005) Neurobiology in primary headaches. Brain Res Brain Res Rev 48:438\u2013456","journal-title":"Brain Res Brain Res Rev"},{"key":"591_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/978-3-540-79090-7_13","volume":"194","author":"VS Seybold","year":"2009","unstructured":"Seybold VS (2009) The role of peptides in central sensitization. Handb Exp Pharmacol 194:451\u2013491","journal-title":"Handb Exp Pharmacol"},{"key":"591_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785\u2013793","journal-title":"Neurotoxicology"},{"key":"591_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1526-4610.2011.01955.x","volume":"51","author":"NT Mathew","year":"2011","unstructured":"Mathew NT (2011) Pathophysiology of chronic migraine and mode of action of preventive medications. Headache 51:84\u201392","journal-title":"Headache"},{"key":"591_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pneurobio.2014.06.001","volume":"119\u2013120","author":"I Matak","year":"2014","unstructured":"Matak I, Lackovi\u0107 Z (2014) Botulinum toxin A, brain and pain. Prog Neurobiol 119\u2013120:39\u201359","journal-title":"Prog Neurobiol"},{"key":"591_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10194-006-0344-9","volume":"7","author":"I Farinelli","year":"2006","unstructured":"Farinelli I, Coloprisco G, De Filippis S, Martelletti P (2006) Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 7:407\u2013412","journal-title":"J Headache Pain"},{"issue":"suppl 1","key":"591_CR23","first-page":"1","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","unstructured":"Headache Classification Subcommittee of the International Headache Society (2004) The International classification of headache disorders-2nd edition. Cephalalgia 24(suppl 1):1\u2013160","journal-title":"Cephalalgia"},{"key":"591_CR24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1468-2982.2006.01172.x","volume":"26","author":"J Olesen","year":"2006","unstructured":"Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, G\u00f6bel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742\u2013746","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"591_CR25","doi-asserted-by":"publisher","first-page":"A137","DOI":"10.1186\/1129-2377-16-S1-A137","volume":"16","author":"A Negro","year":"2015","unstructured":"Negro A, D\u2019Alonzo L, Lala N, Martelletti P (2015) A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine. J Headache Pain 16(Suppl 1):A137. doi: 10.1186\/1129-2377-16-S1-A137","journal-title":"J Headache Pain"},{"key":"591_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1517\/14728214.2012.709846","volume":"17","author":"L Lionetto","year":"2012","unstructured":"Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, Simmaco M, Smith T, Al-Kaisy A, Arcioni R, Martelletti P (2012) Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 17:393\u2013406","journal-title":"Expert Opin Emerg Drugs"},{"key":"591_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ane.12171","volume":"129","author":"SK Aurora","year":"2014","unstructured":"Aurora SK, Dodick DW, Diener HC, Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD et al (2014) Onabotulinumtoxin A for chronic migraine: efficacy, safety and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 129:61\u201370","journal-title":"Acta Neurol Scand"},{"key":"591_CR28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","volume":"86","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD, Dodick WD, Aurora SK, Dienere H-C, DeGryse RE, Lipton RB, Turkel CC (2015) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry 86:996\u20131001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"591_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1129-2377-14-9","volume":"14","author":"C Tana","year":"2013","unstructured":"Tana C, Tafuri E, Tana M, Martelletti P, Negro A, Affaitati G, Fabrizio A, Costantini R, Mezzetti A, Giamberardino MA (2013) New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain 14:9","journal-title":"J Headache Pain"},{"key":"591_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10194-011-0388-3","volume":"12","author":"A Negro","year":"2011","unstructured":"Negro A, Martelletti P (2011) Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 12:593\u2013601","journal-title":"J Headache Pain"},{"key":"591_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10194-011-0334-4","volume":"12","author":"S Aurora","year":"2011","unstructured":"Aurora S, Diener HC, Dodick D, PREEMPT Chronic Migraine Study Group (2011) Reply: clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 12:137\u2013138","journal-title":"J Headache Pain"},{"key":"591_CR32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","volume":"28","author":"S Silberstein","year":"2008","unstructured":"Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ, Task Force of the International Headache Society Clinical Trials Subcommittee (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28:484\u2013495","journal-title":"Cephalalgia"},{"key":"591_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Blumenfield AM, Cady RK, Turner IM, Lipton RB, Deiner HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW (2013) OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 331:48\u201356","journal-title":"J Neurol Sci"},{"key":"591_CR34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1526-4610.2007.00914.x","volume":"48","author":"NT Mathew","year":"2008","unstructured":"Mathew NT, Kailasam J, Meadors L (2008) Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 48:194\u2013200","journal-title":"Headache"},{"key":"591_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10194-011-0339-z","volume":"12","author":"G Sandrini","year":"2011","unstructured":"Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G (2011) Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain 12:427\u2013433","journal-title":"J Headache Pain"},{"key":"591_CR36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pain.2006.09.012","volume":"125","author":"M Jakubowski","year":"2006","unstructured":"Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R (2006) Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 125:286\u2013295","journal-title":"Pain"},{"key":"591_CR37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1526-4610.2005.05067.x","volume":"45","author":"EJ Eross","year":"2005","unstructured":"Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW (2005) Duration of migraine is a predictor for response to botulinum toxin type A. Headache 45:308\u2013314","journal-title":"Headache"},{"key":"591_CR38","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/head.12372","volume":"54","author":"E Cernuda-Moroll\u00f3n","year":"2014","unstructured":"Cernuda-Moroll\u00f3n E, Mart\u00ednez-Camblor P, Ram\u00f3n C, Larrosa D, Serrano-Pertierra E, Pascual J (2014) CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 54:987\u2013995","journal-title":"Headache"},{"key":"591_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/2193-1801-2-377","volume":"2","author":"A Bumb","year":"2013","unstructured":"Bumb A, Seifert B, Wetzel S, Agosti R (2013) Patients profiling for Botox\u00ae (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker. Springerplus 2:377","journal-title":"Springerplus"},{"key":"591_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/j.1526-4610.2007.00953.x","volume":"48","author":"R Cady","year":"2008","unstructured":"Cady R, Schreiber C (2008) Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 48:900\u2013913","journal-title":"Headache"},{"key":"591_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s10194-015-0555-z","volume":"16","author":"J Edvinsson","year":"2015","unstructured":"Edvinsson J, Warfvinge K, Edvinsson L (2015) Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study. J Headache Pain 16:555","journal-title":"J Headache Pain"},{"key":"591_CR42","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","volume":"156","author":"E Cernuda-Moroll\u00f3n","year":"2015","unstructured":"Cernuda-Moroll\u00f3n E, Ram\u00f3n C, Mart\u00ednez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J (2015) OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 156:820\u2013824","journal-title":"Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-016-0591-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-016-0591-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-016-0591-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-016-0591-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T18:09:55Z","timestamp":1718302195000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-016-0591-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["591"],"URL":"https:\/\/doi.org\/10.1186\/s10194-016-0591-3","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"1"}}